BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Duncan RE, Delatycki MB, Collins SJ, Boyd A, Masters CL, Savulescu J. Ethical considerations in presymptomatic testing for variant CJD. J Med Ethics 2005;31:625-30. [PMID: 16269554 DOI: 10.1136/jme.2005.011965] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Sawyer EB, Edgeworth JA, Thomas C, Collinge J, Jackson GS. Preclinical detection of infectivity and disease-specific PrP in blood throughout the incubation period of prion disease. Sci Rep 2015;5:17742. [PMID: 26631638 DOI: 10.1038/srep17742] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
2 Jackson GS, Burk-Rafel J, Edgeworth JA, Sicilia A, Abdilahi S, Korteweg J, Mackey J, Thomas C, Wang G, Schott JM, Mummery C, Chinnery PF, Mead S, Collinge J. Population screening for variant Creutzfeldt-Jakob disease using a novel blood test: diagnostic accuracy and feasibility study. JAMA Neurol 2014;71:421-8. [PMID: 24590363 DOI: 10.1001/jamaneurol.2013.6001] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
3 Paulsen JS, Nance M, Kim JI, Carlozzi NE, Panegyres PK, Erwin C, Goh A, McCusker E, Williams JK. A review of quality of life after predictive testing for and earlier identification of neurodegenerative diseases. Prog Neurobiol 2013;110:2-28. [PMID: 24036231 DOI: 10.1016/j.pneurobio.2013.08.003] [Cited by in Crossref: 70] [Cited by in F6Publishing: 74] [Article Influence: 7.8] [Reference Citation Analysis]
4 Bechtel K, Geschwind MD. Ethics in prion disease. Prog Neurobiol 2013;110:29-44. [PMID: 23906487 DOI: 10.1016/j.pneurobio.2013.07.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
5 Schneider SA, Klein C. What is the role of genetic testing in movement disorders practice? Curr Neurol Neurosci Rep 2011;11:351-61. [PMID: 21465148 DOI: 10.1007/s11910-011-0200-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
6 Edgeworth JA, Farmer M, Sicilia A, Tavares P, Beck J, Campbell T, Lowe J, Mead S, Rudge P, Collinge J, Jackson GS. Detection of prion infection in variant Creutzfeldt-Jakob disease: a blood-based assay. Lancet 2011;377:487-93. [PMID: 21295339 DOI: 10.1016/S0140-6736(10)62308-2] [Cited by in Crossref: 150] [Cited by in F6Publishing: 118] [Article Influence: 13.6] [Reference Citation Analysis]
7 Ryan R, Hill S, Lowe D, Allen K, Taylor M, Mead C. Notification and support for people exposed to the risk of Creutzfeldt-Jakob disease (CJD) (or other prion diseases) through medical treatment (iatrogenically). Cochrane Database Syst Rev 2011;:CD007578. [PMID: 21412905 DOI: 10.1002/14651858.CD007578.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
8 Shuman AG, Wolf GT. Human papillomavirus status in head and neck cancer: the ethics of disclosure. Cancer 2010;116:4221-6. [PMID: 20544838 DOI: 10.1002/cncr.25210] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
9 Buyx AM. Blood Donation, Payment, and Non-Cash Incentives: Classical Questions Drawing Renewed Interest. Transfus Med Hemother 2009;36:329-39. [PMID: 21076552 DOI: 10.1159/000235608] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 1.9] [Reference Citation Analysis]
10 Ryan R, Allen K, Hill S, Lowe D, Ryan R. Notification and support for people exposed to the risk of Creutzfeldt-Jakob disease (CJD) through medical treatment (iatrogenically). Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd007578] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]